Pharma R&D Europe summits series – registration closing
16 May 2014 | By Oxford Global Conferences
Registration is now closing for Oxford Global’s Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe...
List view / Grid view
News
American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates
16 May 2014 | By Pfizer
The American College of Physicians announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination...
Abbott expands Latin American presence and branded generics portfolio with acquisition of CFR Pharmaceuticals
16 May 2014 | By Abbott
Abbott enhances its position in fast-growing Latin American market, more than doubling its branded generics pharmaceutical sales and presence in the region...
GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome
13 May 2014 | By GlaxoSmithKline
GlaxoSmithKline announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome...
Janssen announces expanded collaboration with International Partnership for Microbicides for development and commercialization of dapivirine
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...
Boehringer Ingelheim will make detailed clinical trial data available to the scientific community
12 May 2014 | By Boehringer Ingelheim
In order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program...
Amgen and AstraZeneca announce positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
Lundbeck receives grant from The Michael J. Fox Foundation for biological markers identification in Parkinson’s disease
6 May 2014 | By Lundbeck
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
The end of hepatitis C?
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
MSD and Endocyte announce independent DSMB recommends vintafolide PROCEED Phase 3 trial be stopped for futility following interim analysis
2 May 2014 | By Merck
MSD and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped...
Fibrotech acquired by Shire for US$75M plus milestones
1 May 2014 | By Fibrotech Therapeutics Pty Ltd
Fibrotech announced that it has reached an agreement with Shire plc, under which Shire has agreed to purchase Fibrotech for an upfront payment of $75M...
Johnson & Johnson announces new collaboration with Stop TB Partnership’s Global Drug Facility to enhance access to Anti-TB Compound
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237)
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
Teva and OncoGenex announce top-line survival results of Phase III SYNERGY trial evaluating custirsen in combination with first-line docetaxel and prednisone
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
GSK and MMV announce start of phase III programme of tafenoquine for Plasmodium vivax malaria
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...